These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
491 related articles for article (PubMed ID: 25997815)
1. Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer. Kim HS; Ryu MH; Zang DY; Ryoo BY; Yang DH; Cho JW; Lim MS; Kim MJ; Han B; Choi DR; Kim JH; Jung JY; Song H; Park CK; Kang YK Gastric Cancer; 2016 Apr; 19(2):579-585. PubMed ID: 25997815 [TBL] [Abstract][Full Text] [Related]
2. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02. Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638 [TBL] [Abstract][Full Text] [Related]
3. A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer. Oh SY; Kwon HC; Jeong SH; Joo YT; Lee YJ; Cho Sh; Kang MH; Go SI; Lee GW; Kim Hg; Kang JH Invest New Drugs; 2012 Feb; 30(1):350-6. PubMed ID: 20706861 [TBL] [Abstract][Full Text] [Related]
4. Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer. Sym SJ; Hong J; Jung M; Park J; Cho EK; Lee WK; Chung M; Kim HS; Lee JH; Shin DB Cancer Chemother Pharmacol; 2012 Aug; 70(2):277-84. PubMed ID: 22752217 [TBL] [Abstract][Full Text] [Related]
5. A dose-escalation study of docetaxel, oxaliplatin, and S-1 (DOS) as a first-line therapy for patients with unresectable metastatic gastric cancer. Sato Y; Sagawa T; Ohnuma H; Hirakawa M; Takahashi Y; Hamaguchi K; Fujikawa K; Nobuoka T; Okamoto K; Miyamoto H; Muguruma N; Takemasa I; Takayama T Cancer Chemother Pharmacol; 2019 Jan; 83(1):161-167. PubMed ID: 30406285 [TBL] [Abstract][Full Text] [Related]
6. Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up. Rosenberg AJ; Rademaker A; Hochster HS; Ryan T; Hensing T; Shankaran V; Baddi L; Mahalingam D; Mulcahy MF; Benson AB Oncologist; 2019 Aug; 24(8):1039-e642. PubMed ID: 31138725 [TBL] [Abstract][Full Text] [Related]
7. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Yoshida K; Ninomiya M; Takakura N; Hirabayashi N; Takiyama W; Sato Y; Todo S; Terashima M; Gotoh M; Sakamoto J; Nishiyama M Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3402-7. PubMed ID: 16740764 [TBL] [Abstract][Full Text] [Related]
8. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor. Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955 [TBL] [Abstract][Full Text] [Related]
9. Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11. Kim HS; Ryu MH; Zang DY; Park SR; Han B; Kang WK; Rha SY; Jung M; Kim JS; Kang BW; Lee KH; Rho SY; Kim JH; Kim KC; Cho JW; Choi DR; Lim H; Kang HS; Soh JS; Kim MJ; Seo J; Kang YK Gastric Cancer; 2018 Sep; 21(5):802-810. PubMed ID: 29372461 [TBL] [Abstract][Full Text] [Related]
10. S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial. Hironaka S; Sugimoto N; Yamaguchi K; Moriwaki T; Komatsu Y; Nishina T; Tsuji A; Nakajima TE; Gotoh M; Machida N; Bando H; Esaki T; Emi Y; Sekikawa T; Matsumoto S; Takeuchi M; Boku N; Baba H; Hyodo I Lancet Oncol; 2016 Jan; 17(1):99-108. PubMed ID: 26640036 [TBL] [Abstract][Full Text] [Related]
11. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Al-Batran SE; Hartmann JT; Hofheinz R; Homann N; Rethwisch V; Probst S; Stoehlmacher J; Clemens MR; Mahlberg R; Fritz M; Seipelt G; Sievert M; Pauligk C; Atmaca A; Jäger E Ann Oncol; 2008 Nov; 19(11):1882-7. PubMed ID: 18669868 [TBL] [Abstract][Full Text] [Related]
12. The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial. Anter AH; Abdel-Latif RM Med Oncol; 2013 Mar; 30(1):451. PubMed ID: 23307258 [TBL] [Abstract][Full Text] [Related]
13. Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. Sato Y; Takayama T; Sagawa T; Takahashi Y; Ohnuma H; Okubo S; Shintani N; Tanaka S; Kida M; Sato Y; Ohta H; Miyanishi K; Sato T; Takimoto R; Kobune M; Yamaguchi K; Hirata K; Niitsu Y; Kato J Cancer Chemother Pharmacol; 2010 Sep; 66(4):721-8. PubMed ID: 20041328 [TBL] [Abstract][Full Text] [Related]
14. Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study. Richards D; Kocs DM; Spira AI; David McCollum A; Diab S; Hecker LI; Cohn A; Zhan F; Asmar L Eur J Cancer; 2013 Sep; 49(13):2823-31. PubMed ID: 23747051 [TBL] [Abstract][Full Text] [Related]
15. A phase II study of biweekly oxaliplatin plus S-1 combination chemotherapy as a first-line treatment for patients with metastatic or advanced gastric cancer in China. Xiao C; Qian J; Zheng Y; Song F; Wang Q; Jiang H; Mao C; Xu N Medicine (Baltimore); 2019 May; 98(20):e15696. PubMed ID: 31096513 [TBL] [Abstract][Full Text] [Related]
16. Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer. Di Lauro L; Vici P; Belli F; Tomao S; Fattoruso SI; Arena MG; Pizzuti L; Giannarelli D; Paoletti G; Barba M; Sergi D; Maugeri-Saccà M Gastric Cancer; 2014 Oct; 17(4):718-24. PubMed ID: 24318671 [TBL] [Abstract][Full Text] [Related]
17. A phase II study of modified docetaxel, cisplatin, and S-1 (mDCS) chemotherapy for unresectable advanced gastric cancer. Uemura N; Kikuchi S; Sato Y; Ohnuma H; Okamoto K; Miyamoto H; Hirakawa M; Sagawa T; Fujikawa K; Takahashi Y; Okuda T; Minami S; Takahashi M; Okamoto T; Takada K; Miyanisi K; Takayama T; Kato J Cancer Chemother Pharmacol; 2017 Oct; 80(4):707-713. PubMed ID: 28849257 [TBL] [Abstract][Full Text] [Related]
18. Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer. Zang DY; Yang DH; Kim MJ; Jang KM; Hwang SW; Yoo KS; Han T; Kim HY; Kim HJ; Kwon JH; Song HH; Park S; Jung JY; Kim HS; Kim JH Cancer Chemother Pharmacol; 2009 Oct; 64(5):877-83. PubMed ID: 19190908 [TBL] [Abstract][Full Text] [Related]
19. Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma. Goel G; Jauhri M; Negi A; Aggarwal S Hematol Oncol Stem Cell Ther; 2010; 3(2):55-9. PubMed ID: 20543537 [TBL] [Abstract][Full Text] [Related]
20. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer. Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]